On November 17, amid a broad decline across A-shares, the pharmaceutical and biotech sector (Shenwan classification) fell 0.64%. After dropping 10.26% in the first half of the year, the sector had gained 0.51% cumulatively from the start of the second half through November 17.
Looking ahead to investment directions in the pharmaceutical and biotech industry for 2027, Zhang Jinghan, chief biopharma analyst at Shenwan Hongyuan Research, expressed optimism about three structural themes: "innovative drugs + CXO + AIDD." On November 17, Chen Chen, head of China healthcare research at UBS Securities, also stated that the key investment directions currently favored are biotech, CRO, and AI drug discovery, "which are also the three directions we recommend investors focus on at this stage."
Regarding the biotech sector, Chen Chen said the focus is on three aspects: first, sustainable earnings growth; second, outbound licensing and global collaboration that continuously validate China's commercialization innovation capabilities; and third, a relatively rich pipeline of data readouts and other catalysts over the coming year.
As for what factors to watch in subsequent investment in the pharmaceutical and biotech industry, multiple analysts believe that sub-sectors within A-share biopharma will diverge, with a relatively favorable view on the going-global logic, while noting risks such as innovative drug overseas expansion falling short of expectations, R&D failures and clinical progress delays, innovative drug R&D spending below expectations, and intensifying technological iteration and market competition.
Three key themes of innovative drugs, CRO, and AI pharma draw attention
Over the past few years, a major concern in the market about Chinese innovative drug companies has been whether their business models can ultimately achieve profitability. "This question is now being gradually answered: on one hand, as core product sales continue to grow, economies of scale are becoming evident; on the other hand, persistently active outbound licensing is also bringing additional revenue and profit contributions to the industry," Chen Chen said.
In terms of data, 91 A-share and H-share listed biopharmaceutical companies collectively earned approximately 5.5 billion RMB in the first half of 2026, compared to a combined loss of approximately 7.4 billion RMB in the first half of 2025. "Based on the companies we cover, most are expected to reach break-even around 2027. We believe the market's investment logic for Chinese BioTech is shifting from a past focus on R&D pipelines and individual clinical data toward a more mature framework, namely whether this innovation capability can ultimately translate into revenue, profit, and cash flow," Chen Chen stated.
Outbound licensing and collaboration represent one of the most important structural changes in China's innovative drug industry in recent years. From the beginning of 2026 to date, the total value and upfront payments of outbound licensing deals by Chinese pharmaceutical companies have both exceeded full-year 2025 levels. The market is now focused not just on the number of deals, but on whether these collaborations can truly move forward. Chen Chen noted that a major highlight of 2026 is the continuous emergence of new licensing and collaboration deals, gradually extending from one-way licensing to combination-type and platform-type collaborations, which signifies global pharmaceutical companies' recognition of China's innovation capabilities. At the same time, changes in relevant regulations also need to be monitored.
Regarding catalysts in the innovative drug space over the coming year, Chen Chen believes the most important is to watch for readouts of key clinical data, among which "ivonescimab" is expected to read out important global Phase III clinical trial results within the next six months, making it one of the catalysts the market is closely watching. In addition, approvals of new products and new indications, as well as the price reduction magnitude for most products following the implementation of the 2026 national medical insurance negotiations, are also important points of focus.
The CRO (pharmaceutical R&D outsourcing) industry is also a key direction of market attention. Since 2026, CRO and CDMO (contract research, development, and manufacturing organizations) companies have seen significant growth in both new and backlog orders, mainly benefiting from increased global R&D demand and the experimental validation needs of emerging AI pharma (AIDD/AI4S).
"We see that domestic R&D demand is continuing to recover. As the biopharmaceutical financing environment improves, domestic R&D activities will gradually pick up, and we have also observed some price recovery in the industry. In terms of stages, the recovery trend in preclinical business may currently be more pronounced than in the clinical stage," Chen Chen said, adding that improved financing will ultimately transmit to R&D activities, which will further transmit to CRO and CDMO orders.
From a biopharmaceutical financing perspective, global biopharma financing reached approximately $55.4 billion in the first nine months of 2026, up 83% year-on-year and up 71% compared to the same period in 2019. China's financing environment is also improving, with total financing of approximately 85.9 billion RMB in the first ten months of 2026, up 6% year-on-year and up 51% compared to the same period in 2019.
The changes and impact that AI brings to the pharmaceutical and biotech industry are also a hot topic of current market discussion. Chen Chen believes that large biopharmaceutical companies and CDMO firms may benefit from the AIDD trend, as large enterprises may possess more resources and internal data for developing AIDD capabilities; AIDD may generate numerous experimental validation needs and may help direct molecule production and validation-related orders to CDMO companies. Preclinical and early-stage clinical demand may increase, but the more expensive Phase III clinical trials and the trend of filing for market approval based on Phase III data remain to be observed.
"We have already seen biopharmaceutical companies using AIDD (artificial intelligence drug design) to varying degrees, and we expect further increases in the application of AIDD in the future," Chen Chen said.
Sub-sector divergence intensifies, going-global logic favored
From the beginning of this year through November 17, the pharmaceutical and biotech (Shenwan) index fell 9.80% cumulatively, mainly due to a decline of over 10% in the first half, with a slight gain since the start of the second half. Over the same period, the Wind All-A index fell over 15%. So how might the pharmaceutical and biotech industry evolve going forward, and what core factors need to be monitored?
"The A-share biopharma sector will still see divergence among sub-industries. Different sub-industries have different sources of revenue and profit, and face different consumers and payers," Chen Chen told Yicai Global.
She analyzed in detail that, relatively speaking, she is less optimistic about sub-sectors whose revenue and profit come entirely from within China, because China faces an aging population structure, and medical insurance cost control is an inevitable trend. Therefore, if biopharmaceutical companies only serve the domestic market, it will be difficult to achieve high profit margins, and subsequent growth will be relatively challenging.
"For example, the distribution industry, traditional Chinese medicine, pharmacies, hospitals, and the blood products industry all follow domestic logic. Under the overall trend of cost control, I remain relatively conservative and cautious about industries that rely on the domestic market," Chen Chen said.
By contrast, Chen Chen is relatively optimistic about the going-global logic. She believes that companies accelerating internationalization and earning overseas revenue have better prospects and paths forward. Chen Chen gives priority recommendation to three sub-sectors: innovative drugs, CRO, and AI pharma. Regarding innovative drugs, she believes that the proportion of innovative drugs in the total medical insurance fund pool is still small, leaving significant room for growth in the future. While domestic market revenue growth may not experience explosive growth, it is unlikely to decline either, and the main driver is increased revenue from outbound licensing.
According to UBS Securities estimates, the average cash runway for BioTech companies overall has increased from 2.8x at the end of 2025 to 3.4x in the first half of 2026. Although the cash position of biotech companies is improving, Chen Chen cautioned that improvement in the average does not mean all companies have resolved their funding pressures. The cash runway across different companies remains highly divergent. Therefore, when selecting BioTech companies, one cannot only look at their pipelines and clinical data, but must also consider commercialization capability, outbound licensing capability, and balance sheet safety.
For CRO and CDMO companies, "the major clients of leading companies are not domestic pharmaceutical companies; their main revenue sources are overseas large pharmaceutical companies, so we can see that their order books are relatively full, and future growth rates are expected to be high due to the better global financing recovery," Chen Chen told reporters.
Regarding AI pharma, there is currently no drug globally that has been entirely designed by AI, passed Phase III clinical trials, and been commercially launched. The industry remains in an observation and validation stage for AI pharma overall. "This is at least the direction of the future, a scientific breakthrough worth looking forward to," Chen Chen said, noting that what we see now is that AI pharma can indeed improve drug R&D efficiency in certain aspects.
Zhang Jinghan stated that over the past few years, global pharmaceutical companies and technology companies have continued to increase their investment in the AIDD field. Over the next two years, as AI-assisted new drugs are formally approved and launched and Phase III clinical results are successively read out, AIDD is moving from the "proof of concept" stage to the "clinical validation" stage.
Regarding risks to watch in subsequent investment, a brokerage analyst noted four major risk factors: first, innovative drug overseas expansion falling short of expectations—although Chinese pharmaceutical companies' outbound licensing deal values have repeatedly hit new highs, their share in the global innovative drug market remains relatively limited, and the accumulation of international recognition and substantive expansion of share will still take time; second, R&D failures in core pipelines and delays in clinical progress, which may have a materially adverse impact on companies' future profitability; third, innovative drug R&D spending below expectations—since most CXO industry orders come from innovative drug companies' R&D expenditures, a decline in innovative drug companies' R&D spending would adversely affect the industry; fourth, rapid technological iteration and increasingly fierce competition in the AI pharma field.
Comments